Aspira Pathlab & Diagnostics Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 1002885, "name": "Aspira Pathlab", "stock_name": "Aspira Pathlab", "full_name": "Aspira Pathlab & Diagnostics Ltd", "name_url": "stocks-analysis/aspira-pathlab", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "56.02", "chg": -0.98, "chgp": "-1.72%", "dir": -1, "prev_price": "57.00", "mcapval": "59.00 Cr", "mcap": "Micro Cap", "scripcode": 540788, "symbol": "", "ind_name": "Healthcare Services", "ind_code": 94, "indexname": "", "isin": "INE500C01017", "curr_date": "Mar 05", "curr_time": "", "bse_nse_vol": 259, "exc_status": "Active", "traded_date": "Mar 05, 2026", "traded_date_str": "2026 03 05", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aspira-pathlab-1002885-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-amp-diagnostics-ltd-is-rated-strong-sell-3873246", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AspiraPathlabDi_mojoScore_3873246.png", "date": "2026-03-05 10:10:02", "description": "Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 05 March 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Aspira Pathlab & Diagnostics Downgraded to Strong Sell Amid Financial and Technical Weakness", "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-downgraded-to-strong-sell-amid-financial-and-technical-weakness-3841909", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AspiraPathlabDi_mojoScore_3841909.png", "date": "2026-02-16 08:38:03", "description": "Aspira Pathlab & Diagnostics Ltd has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its financial performance, valuation metrics, technical indicators, and overall quality. The downgrade reflects significant deterioration in quarterly earnings, a shift in technical trends, and a reassessment of valuation attractiveness, signalling heightened caution for investors in the healthcare services sector." }, { "title": "Aspira Pathlab Falls 9.45%: 3 Key Factors Driving the Weekly Decline", "link": "https://www.marketsmojo.com/news/stocks-in-action/aspira-pathlab-falls-945-3-key-factors-driving-the-weekly-decline-3839359", "imagepath": "", "date": "2026-02-14 12:01:06", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>9 Feb:</strong> Stock opens at ₹67.99, up 1.67% on positive technical upgrade</p>\n <p><strong>10 Feb:</strong> Mojo Grade upgraded to Hold by MarketsMOJO</p>\n <p><strong>11 Feb:</strong> Q1 FY26 results reveal profitability surge but operational challenges</p>\n <p><strong>12 Feb:</strong> Valuation grade downgraded amid sharp price decline</p>\n <p><strong>13 Feb:</strong> Week closes at ₹60.55, down 1.26% on final trading day</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">₹66.87</d..." }, { "title": "Aspira Pathlab & Diagnostics Ltd: Valuation Shift Signals Changing Market Sentiment", "link": "https://www.marketsmojo.com/news/stocks-in-action/aspira-pathlab-diagnostics-ltd-valuation-shift-signals-changing-market-sentiment-3834324", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AspiraPathlabDi_valuationdot_3834324.png", "date": "2026-02-12 08:04:53", "description": "Aspira Pathlab & Diagnostics Ltd has experienced a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside peer comparisons and historical benchmarks. Investors are now reassessing the stock’s price attractiveness within the healthcare services sector, as the company’s financial metrics and market performance reveal a complex picture." }, { "title": "Aspira Pathlab Q1 FY26: Profitability Surge Masks Underlying Operational Challenges", "link": "https://www.marketsmojo.com/news/result-analysis/aspira-pathlab-q1-fy26-profitability-surge-masks-underlying-operational-challenges-3832988", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AspiraPathlabDi_quaterlyResult_3832988.png", "date": "2026-02-11 09:47:53", "description": "Aspira Pathlab & Diagnostics Ltd., a Mumbai-based pathology specialist with pan-India presence, reported a dramatic turnaround in profitability for Q1 FY26, posting a consolidated net profit of ₹0.42 crores compared to a loss of ₹0.01 crores in Q1 FY25—marking an impressive 740.00% year-on-year growth. However, the quarter-on-quarter trajectory reveals a more concerning narrative, with net profit declining 38.24% from ₹0.68 crores in Q4 FY25, whilst the stock retreated 5.88% in recent trading to close at ₹64.00, reflecting investor caution about the company's near-term prospects." }, { "title": "Are Aspira Pathlab & Diagnostics Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-aspira-pathlab-diagnostics-ltd-latest-results-good-or-bad-3831604", "imagepath": "", "date": "2026-02-10 19:37:38", "description": "Aspira Pathlab & Diagnostics Ltd's latest financial results for Q2 FY26 reveal a complex picture of operational performance. The company reported net sales of ₹5.25 crores, reflecting a year-on-year growth of 13.15% compared to ₹4.64 crores in Q2 FY25. However, this represents a sequential decline of 9.17% from ₹5.78 crores in Q1 FY26, indicating volatility in revenue generation that may raise concerns about demand consistency.\n\nNet profit for the quarter stood at ₹0.42 crores, which is a significant drop of 38.24% quarter-on-quarter from ₹0.68 crores in Q1 FY26, although it marks a substantial improvement from a net profit of ₹0.05 crores in Q2 FY25. This sharp decline in profitability highlights challenges in maintaining consistent operational efficiency, particularly as the operating margin contracted to 13.90%, down from 16.78% in the previous quarter. The margin compression suggests that rising costs a..." }, { "title": "Aspira Pathlab & Diagnostics Ltd Upgraded to Hold by MarketsMOJO on Technical and Financial Strength", "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-ltd-upgraded-to-hold-by-marketsmojo-on-technical-and-financial-strength-3830138", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AspiraPathlabDi_mojoScore_3830138.png", "date": "2026-02-10 08:49:07", "description": "Aspira Pathlab & Diagnostics Ltd has seen its investment rating upgraded from Sell to Hold, reflecting improved technical indicators and robust financial performance. The healthcare services company’s recent quarterly results and evolving market trends have contributed to a more favourable outlook, although valuation metrics suggest cautious optimism remains warranted." }, { "title": "Why is Aspira Pathlab & Diagnostics Ltd falling/rising?", "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-aspira-pathlab-diagnostics-ltd-fallingrising-3825449", "imagepath": "", "date": "2026-02-07 00:45:58", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Strong Intraday Performance and Market Outperformance</strong></p>\n<p>The stock opened with a gap up of 6.65%, signalling robust buying interest from the outset of trading on 06-Feb. It reached an intraday high of ₹67, maintaining a narrow trading range of just ₹0.13, which suggests a consolidation phase after the initial surge. This price action indicates confidence among investors, as Aspira Pathlab outperformed its sector by 6.38% on the day, a considerable margin that highlights its relative strength within the healthcare services space.</p>\n<p>Moreover, the stock is trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – a technical indicator often interpreted as a bullish signal. This alignment of moving averages suggests sustained upward momentum and a po..." }, { "title": "When is the next results date for Aspira Pathlab & Diagnostics Ltd?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-aspira-pathlab-diagnostics-ltd-3823255", "imagepath": "", "date": "2026-02-05 23:18:36", "description": "The next results date for Aspira Pathlab & Diagnostics Ltd is scheduled for 10 February 2026...." } ], "total": 6136, "sid": "1002885", "stock_news_url": "https://www.marketsmojo.com/news/aspira-pathlab-diagnostics-1002885" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "26-Feb-2026", "details": "Newspaper Advertisement regarding Special Window Re-Lodgement for Transfer & Dematerialisation of Physical Securities.", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "12-Feb-2026", "details": "Newspaper Publication for Unaudited Standalone Financial Results for the third quarter & nine months ended on 31.12.2025", "source": "BSE" }, { "caption": "Unaudited Standalone Financial Results & Limited Review Report For Quarter Ended December 31 2025", "datetime": "10-Feb-2026", "details": "Q3/2025-26 Financial Results", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

9 Feb: Stock opens at ₹67.99, up 1.67% on positive technical upgrade

10 Feb: Mojo Grade upgraded to Hold by MarketsMOJO

11 Feb: Q1 FY26 results reveal profitability surge but operational challenges

12 Feb: Valuation grade downgraded amid sharp price decline

13 Feb: Week closes at ₹60.55, down 1.26% on final trading day

Week Open

₹66.87Read full news article

Aspira Pathlab & Diagnostics Ltd: Valuation Shift Signals Changing Market Sentiment

2026-02-12 08:04:53

Aspira Pathlab & Diagnostics Ltd has experienced a notable shift in its valuation parameters, moving from a very attractive to an attractive rating. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside peer comparisons and historical benchmarks. Investors are now reassessing the stock’s price attractiveness within the healthcare services sector, as the company’s financial metrics and market performance reveal a complex picture.

Read full news article

Aspira Pathlab Q1 FY26: Profitability Surge Masks Underlying Operational Challenges

2026-02-11 09:47:53

Aspira Pathlab & Diagnostics Ltd., a Mumbai-based pathology specialist with pan-India presence, reported a dramatic turnaround in profitability for Q1 FY26, posting a consolidated net profit of ₹0.42 crores compared to a loss of ₹0.01 crores in Q1 FY25—marking an impressive 740.00% year-on-year growth. However, the quarter-on-quarter trajectory reveals a more concerning narrative, with net profit declining 38.24% from ₹0.68 crores in Q4 FY25, whilst the stock retreated 5.88% in recent trading to close at ₹64.00, reflecting investor caution about the company's near-term prospects.

Read full news article

Are Aspira Pathlab & Diagnostics Ltd latest results good or bad?

2026-02-10 19:37:38

Aspira Pathlab & Diagnostics Ltd's latest financial results for Q2 FY26 reveal a complex picture of operational performance. The company reported net sales of ₹5.25 crores, reflecting a year-on-year growth of 13.15% compared to ₹4.64 crores in Q2 FY25. However, this represents a sequential decline of 9.17% from ₹5.78 crores in Q1 FY26, indicating volatility in revenue generation that may raise concerns about demand consistency. Net profit for the quarter stood at ₹0.42 crores, which is a significant drop of 38.24% quarter-on-quarter from ₹0.68 crores in Q1 FY26, although it marks a substantial improvement from a net profit of ₹0.05 crores in Q2 FY25. This sharp decline in profitability highlights challenges in maintaining consistent operational efficiency, particularly as the operating margin contracted to 13.90%, down from 16.78% in the previous quarter. The margin compression suggests that rising costs a...

Read full news article

Aspira Pathlab & Diagnostics Ltd Upgraded to Hold by MarketsMOJO on Technical and Financial Strength

2026-02-10 08:49:07

Aspira Pathlab & Diagnostics Ltd has seen its investment rating upgraded from Sell to Hold, reflecting improved technical indicators and robust financial performance. The healthcare services company’s recent quarterly results and evolving market trends have contributed to a more favourable outlook, although valuation metrics suggest cautious optimism remains warranted.

Read full news article

Why is Aspira Pathlab & Diagnostics Ltd falling/rising?

2026-02-07 00:45:58

Strong Intraday Performance and Market Outperformance

The stock opened with a gap up of 6.65%, signalling robust buying interest from the outset of trading on 06-Feb. It reached an intraday high of ₹67, maintaining a narrow trading range of just ₹0.13, which suggests a consolidation phase after the initial surge. This price action indicates confidence among investors, as Aspira Pathlab outperformed its sector by 6.38% on the day, a considerable margin that highlights its relative strength within the healthcare services space.

Moreover, the stock is trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – a technical indicator often interpreted as a bullish signal. This alignment of moving averages suggests sustained upward momentum and a po...

Read full news article

When is the next results date for Aspira Pathlab & Diagnostics Ltd?

2026-02-05 23:18:36

The next results date for Aspira Pathlab & Diagnostics Ltd is scheduled for 10 February 2026....

Read full news article

View All News